中國醫藥(600056.SH):子公司獲得奧拉西坦注射液藥品註冊批件
格隆匯 7 月 6日丨中國醫藥(600056.SH)公佈,近日,公司下屬全資子公司天方藥業有限公司(“天方有限”)收到國家藥品監督管理局(“國家藥監局”)核准簽發的奧拉西坦注射液《藥品註冊批件》。
該類藥品為吡拉西坦的類似物,可改善老年性痴呆和記憶障礙症患者的記憶和學習功能,適用於腦損傷及其引起的神經功能缺失、記憶與智能障礙等症的治療。
根據國家藥監局網站數據查詢顯示,截止目前,該類藥品在國內有石藥集團歐意藥業有限公司、哈爾濱三聯藥業股份有限公司、廣東世信藥業有限公司等11家企業獲批,規格為5ml:1g、20ml:4g、20ml:6g。
根據PDB數據庫樣本醫院用藥銷售統計顯示,2019年奧拉西坦注射液國內樣本醫院銷售總額約為10.21億元。
對該類藥品的研發,有助於擴充並豐富天方有限的產品線。公司高度重視藥品研發,並嚴格控制藥品研發、製造及銷售環節的質量及安全。由於醫藥產品具有高科技、高風險、高附加值的特點,不僅藥品的前期研發以及產品從研製、臨牀試驗報批到投產的週期長、環節多,而且藥品獲得批件後上市銷售也容易受到一些不確定性因素的影響,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.